Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Subtype terms (6)
More specific conditions that are subtypes of Lymphoma, B-Cell in the MeSH hierarchy.
- Burkitt Lymphoma
171 drugs (99 approved, 72 experimental)
- Lymphoma, AIDS-Related
41 drugs (30 approved, 11 experimental)
- Lymphoma, B-Cell, Marginal Zone
235 drugs (117 approved, 118 experimental)
- Lymphoma, Large B-Cell, Diffuse
490 drugs (193 approved, 297 experimental)
- Lymphoma, Primary Effusion
14 drugs (11 approved, 3 experimental)
- Lymphomatoid Granulomatosis
80 drugs (54 approved, 26 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (18)
Phase 3 trials (16)
Phase 2 trials (163)
- allopurinol
- sd-101
- thalidomide
- methylprednisolone
- mercaptopurine
- ibritumomab tiuxetan
- acalabrutinib
- aeg35156
- allogeneic natural killer cells
- alx148
- maraviroc
- Gusacitinib
- bendamustine
- bi-1206
- brentuximab vedotin
- busulfan
- tlk286
- car t cells
- Iberdomide
- lenalidomide
- clofarabine
- polatuzumab vedotin
- denileukin diftitox
- selinexor
- dt2219arl
- durvalumab
- e7777
- eltrombopag
- enzastaurin
- folic acid
- +133 more
Phase 1 trials (130)
- roflumilast
- 19-28z t cells
- decitabine
- ac0010ma
- aroplatin
- autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- azd6738
- blinatumomab
- spebrutinib
- temsirolimus
- cpi-1205
- cudc-907
- di-b4
- dtrm-505
- dtrm-555
- dtrmwxhs-12
- aldesleukin
- hydrocortisone
- ic9-car19 cells
- id-klh vaccine
- igg-rfb4-smpt-dga
- ka2237
- alisertib
- allogeneic stem cells
- pentostatin
- carmustine
- qs-21
- ipilimumab
- ro6870810
- +100 more
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (102)
- Janssen Pharmaceutica NV
- Peking University
- Celgene
- ICON
- Denovo BioPharma
- Shandong University
- ADC Therapeutics SARL
- Chinese Academy of Medical Sciences
- Fondation ARC
- Amgen
- MorphoSys
- Columbia University
- Nanjing Medical University
- Government of Russia
- Fondazione Italiana Diabete Onlus
- Guangzhou Medical University
- Fudan University
- National Heart, Lung, and Blood Institute (NHLBI)
- Russian Academy of Medical Sciences
- University of Brescia
- Center for International Blood and Marrow Transplant Research
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Czech Lymphoma Study Group
- Acerta Pharma
- Chinese Anti-Cancer Association
- Johnson and Johnson
- Merck Serono
- Key Oncologics (Pty) Ltd
- Mayo Clinic
- Roche
- +72 more
Organization Involved with Phase 2 Indications (327)
- Wayne State University
- Tel Aviv University
- Ohio State University
- Stony Brook University
- Northwestern University
- Swedish Orphan Biovitrum
- University of Chicago
- Government of Taiwan
- Genzyme
- The Leukemia and Lymphoma Society
- Indiana University
- Centre Hospitalier COMPIEGNE
- University of North Carolina at Chapel Hill
- Hallym University
- Molecular Templates
- The Alfred Hospital
- Kyungpook University
- Italian Lymphoma Foundation
- Duke University
- Taichung Veterans General Hospital
- Huizhou People's Central Hospital
- Eisai
- Ortho Biotech, Inc.
- University of Pavia
- Swiss Group for Clinical Cancer Research
- Assistance Publique - Hôpitaux de Paris
- Regeneron
- University of Nottingham
- Consortium for Improving Survival of Lymphoma
- Sinocelltech Ltd.
- +297 more
Organization Involved with Phase 1 Indications (104)
- V Foundation
- Thor Medical
- Saint John Regional Hospital
- Medical University of South Carolina
- Caribou Biosciences
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Leukemia Research Foundation
- Union Stem Cell & Gene Engineering Co.LTD
- Acea Bio
- Otsuka
- Yeshiva University
- Agenus Inc.
- Shanghai Celluar Biopharmaceutical Group Ltd.
- Austin Health
- Oncotartis, Inc.
- CLL Consortium
- Nanjing Bioheng Biotech Co., Ltd.
- Xijing Hospital
- Aeon Therapeutics (Shanghai) Co., Ltd.
- Henan Hualong Biotechnology Company
- Chiltern International
- Hainan Medical College
- Barts & The London NHS Trust
- Methodist Cancer Center, Houston, Texas
- Tsinghua University
- Constellation Pharmaceuticals
- Baylor University
- Guizhou Medical University
- miRagen Therapeutics, Inc.
- Sutro Biopharma
- +74 more
Organization Involved with Other Experimental Indications (11)